Investment Thesis
NeoGenomics exhibits troubling fundamental deterioration with operating losses of -$18.2M, negative free cash flow of -$13.1M, and inability to cover debt interest despite 10.1% revenue growth. The disconnect between top-line growth and bottom-line losses signals structural operational inefficiencies, and the company's unsustainable cash burn trajectory poses solvency concerns even with adequate current liquidity.
Strengths
- Revenue growth of 10.1% year-over-year demonstrates ongoing market demand for testing laboratory services
- Strong liquidity position with current ratio of 4.42x and $146.1M in cash reserves provides near-term runway
- Gross margin of 43.3% indicates reasonable pricing power and acceptable core unit economics at the operating level
Risks
- Negative operating cash flow of -$8.1M and free cash flow of -$13.1M indicate operational cash burn is unsustainable
- Negative interest coverage ratio of -10.8x demonstrates inability to service $341.9M debt from operations, creating material refinancing risk
- Operating and net losses persist despite revenue growth, suggesting structural cost structure issues or margin compression problems requiring immediate resolution
Key Metrics to Watch
- Quarterly operating cash flow trajectory toward positive generation and timeline to profitability
- Operating margin expansion rate and effectiveness of management's cost reduction initiatives
- Debt refinancing requirements and covenant compliance given negative earnings and EBITDA position
Financial Metrics
Revenue
186.7M
Net Income
-17.1M
EPS (Diluted)
$-0.21
Free Cash Flow
-13.1M
Total Assets
1.3B
Cash
146.1M
Profitability Ratios
Gross Margin
43.3%
Operating Margin
-9.8%
Net Margin
-9.2%
ROE
-2.1%
ROA
-1.3%
FCF Margin
-7.0%
Balance Sheet & Liquidity
Current Ratio
4.42x
Quick Ratio
4.06x
Debt/Equity
0.41x
Debt/Assets
38.5%
Interest Coverage
-10.83x
Long-term Debt
341.9M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-06T13:29:23.183104 |
Data as of: 2026-03-31 |
Powered by Claude AI